Upload
adele-wilkerson
View
216
Download
1
Embed Size (px)
Citation preview
What’s new in NETs?
Lucy WallConsultant Medical Oncologist
Ann Edgar Patient Forum10th May 2013
What’s new in NETs?
What practice-changing studies have recently been published?
What new treatments to control hormone symptoms might be on the horizon?
What are the potential new treatment options targeting disease control in NETs?
Update on trials to compare and assess new and existing treatment options
In the last few years, 3 big randomised studies have been published:
Promid Study Sunitinib Study in pancreatic NETs Everolimus study in pancreatic NETs
Promid Study
People with inoperable small intestinal NETs
Didn’t need somatostatin analogues for symptom control
Octreoscan positive Received either injections of
sandostatin or placebo
Slide showing graph of time to treatment progression removed due to copyright issues.
Sunitnib in pancreatic NETs
Sunitinib is a tablet treatment that is targeted to block certain molecular processes within the cell
One of its effects is to block blood vessel formation
On scans NETs are much richer in blood vessels than some other tumours
Does blocking blood vessels help to control NET tumours?
Sunitnib in pancreatic NETs
Sunitinib or placebo (dummy tablets) given to people with pancreatic NETs
Disease followed very closely on scan If disease got worse on scan and had been
taking dummy tablets, crossed over to sunitinib
Study closed earlier than initially planned (after recruitment of 171 patients) on advice of data monitoring committee
Slide showing difference in time to disease progression removed due to copyright issues
Everolimus in pancreatic NETs
This is another targeted drug It acts to inhibit the protein mTOR, which
is highly expressed in NET tumours 410 people with low or intermediate grade
pancreatic NETs randomised between everolimus and placebo
At the time of progression, if people had been on placebo, they could be crossed over to active drug
Slide showing difference in time to disease progression removed due to copyright issues
Update from ENETs 2013
Treatments to control hormone symptoms
Brand new treatment options Trials to compare and assess new
and existing treatment options
Hormone symptoms
Telotristat etiprate (LX1606) is a new tablet treatment which acts by inhibiting the enzyme tryptophan hydroxylase.
This enzyme makes serotonin in the body
Serotonin is (at least partly) responsible for the hormonal symptoms of carcinoid (the diarrhoea and flushing that some people get)
Pavel et al 2013
Telestar
When given to 15 people with diarrhoea, the number of bowel motions per day reduced, on average, by 43%
Flushing was also reduced The drug didn’t seem to have a lot of
side effects There will be a randomised trial of this
compound opening soon - Telestar
Telestar
People with small intestinal NETs whose bowels are open more than 4x per day will either get the real tablet (250mg or 500mg tid) or a dummy tablet over a 12 week period.
They’ll fill in questionnaires about flushing, diarrhoea and abdominal pain.
After 12 weeks they will be able to continue on the tablet if they are helped by it
Pasireotide (SOM 230)
This is a somatostatin analogue like sandostatin and lanreotide, but is thought to be more potent
In people whose symptoms were no longer controlled by sandostatin, pasiretode helped with hormonal symptoms in about ¼
Kvols et al 2012
New treatment options 1 - SSA for disease control?
For patients with small intestinal NETs we know that sandostatin can help to slow down tumour growth?
Do SSA stabilise non-SI NETs? Clarinet study – in patients with NETs
but no syndrome, does lanreotide control disease for longer than placebo?
Clarinet
Close radiological follow up for 2 years
On progression unblinded and crossed over to drug if had been on placebo
Due to report results this year
Co-operate-2
In patients with pancreatic NETs on everolimus will the addition of pasireotide control the disease for longer than everolimus alone?
The trial has completed recruitment, but results not yet available
New treatment options2 - anti-angiogenic therapy?
SWOG0518 Patients with ‘poor prognosis
carcinoid’ – generally disease growing although some other high risk patient groups also included
Randomized trial • octreotide acetate + recombinant
interferon alfa-2b• octreotide acetate + bevacizumab
SWOG0518
Interferon alfa-2b has been used in NETs for a long time with equivocal evidence of efficacy. It is known to inhibit the development of blood vessels (amongst many other things)
Bevacizumab is an antibody that blocks the formation of new blood vessels. It is currently licensed for the treatment of colorectal cancer
Everolimus and Octreotide With or Without Bevacizumab
This randomized phase II trial is studying how well giving everolimus and octreotide together with or without bevacizumab works in treating patients with locally advanced or metastatic pancreatic neuroendocrine tumors that cannot be removed by surgery
It has completed recruitment, but no results are available yet
New treatment options3 – everolimus in non-pancreatic tumours?
Radiant 4 Everolimus has been shown to control
pancreatic NETs for longer than placebo. A parallel trial in non-pancreatic NETs was
strongly suggestive of efficacy, but unfortunately wasn’t considered strong enough evidence to give everolimus to other NET patients
Radiant-4
People with NETs of lung or GI origin which have progressed within the previous 6 months will either receive everolimus or placebo
Their disease will be closely monitored so they can be switched to an alternative treatment if the tumour progresses
Co-operate-1
Patients with GI or pulmonary NETs Exploring the role of pasireotide and
everolimus in disease control
Co-operate-1Arms Assigned Interventions
Experimental: Functional tumors, pre-treated
Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus
Experimental: Functional tumors, treatment naïve
Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus
Experimental: Nonfunctional tumors, pretreated 1
Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus
Experimental: Nonfunctional tumors, pretreated 2
Drug: Everolimus followed by Pasireotide LAR + Everolimus
Experimental: Nonfunctional tumors, treatment-naïve 1
Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus
Experimental: Nonfunctional tumors, treatment-naïve 2
Drug: Everolimus followed by Pasireotide LAR + Everolimus
Sunland Study A randomised, placebo-controlled
trial to see if the addition of sunitinib to lanreotide therapy in patients with progressing midgut NETs can be associated with longer disease control than lanreotide alone
New treatment options4 – sunitnib in non-pancreatic tumours?
• Pazopanib is a multi-targeted agent that has already shown clinical activity in patients with advanced NETs and also decreases blood flow and permeability surface on functional CT scans.
Phase II trial of small intestinal and pancreatic NETs which had progressed within the last 12 months
44 patients treated At 6 months 85.7% of people hadn’t progressed On average 10 months until disease did progress
New treatment options5 – pazopanib
Grande et al 2012
Trial of chemotherapy in pancreatic NETs
Temsirolimus is an mTOR inhibitor (grandfather of everolimus)
Bevacizumab is an anti-angiogenic antibody used in the treatment of colorectal cancer
This is a phase II (no comparison) trial of 50 people
New treatment options6 – temsirolimus + bevacizumab ?
Hobday et al 2012
Patients had progressive disease in the 7 months before study entry
13 of the first 25 patients had disease shrinkage on the treatment (52%)
New treatment options6 – temsirolimus + bevacizumab ?
Hobday et al 2012
Currently under development as an anti-cancer treatment in a number of tumour types
Being used to treat pancreatic NETs that have progressed after everolimus
No results available at present
New treatment options7 – BEZ235 ??
NETTER-1 trial Patients with inoperable or
metastatic progressive SS receptor positive tumours
Treatments • 4 treatments with 177Lu-DOTA0-Tyr3-
Octreotate• Octreotide LAR 60mg every 4 weeks
How/ when to use current treatment options?
Seqtor study Patients with inoperable or
metastatic pancreatic NETs Is disease control better with
chemotherapy followed by everolimus or the reverse sequence?
How/ when to use current treatment options?
Where are we at
Significant increase in trials in NETs over the last 5 years
Many trials underway with results awaited within the next couple of years
The hope is that people will be able to have several new therapies consecutively
Unfortunately Scottish government doesn’t fund cancer trials networks to the same level as English government so difficult to support all trials locally